Pivotal trial of benzoyl peroxide/clindamycin 1.2%/3.75% gel (Onexton) for the treatment of moderate to severe acne.

Trial Profile

Pivotal trial of benzoyl peroxide/clindamycin 1.2%/3.75% gel (Onexton) for the treatment of moderate to severe acne.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs Benzoyl peroxide/clindamycin (Primary)
  • Indications Acne vulgaris
  • Focus Registrational; Therapeutic Use
  • Sponsors Bausch Health Companies; Valeant Pharmaceuticals International
  • Most Recent Events

    • 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
    • 05 Dec 2014 New trial record
    • 25 Nov 2014 Results published in a Valeant Pharmaceuticals International media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top